BioNote, Inc. (377740.KS)
- Previous Close
4,575.00 - Open
4,575.00 - Bid 4,575.00 x --
- Ask 4,590.00 x --
- Day's Range
4,550.00 - 4,625.00 - 52 Week Range
3,990.00 - 6,400.00 - Volume
12,447 - Avg. Volume
71,748 - Market Cap (intraday)
464.233B - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 200.00 (4.37%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
--
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical devices. BioNote, Inc. was founded in 2003 and is headquartered in Hwaseong-si, South Korea.
www.bionote.co.krRecent News: 377740.KS
View MorePerformance Overview: 377740.KS
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 377740.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 377740.KS
View MoreValuation Measures
Market Cap
463.73B
Enterprise Value
62.24B
Trailing P/E
8.44
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.54
Price/Book (mrq)
0.28
Enterprise Value/Revenue
0.61
Enterprise Value/EBITDA
0.76
Financial Highlights
Profitability and Income Statement
Profit Margin
53.77%
Return on Assets (ttm)
0.46%
Return on Equity (ttm)
3.46%
Revenue (ttm)
102.78B
Net Income Avi to Common (ttm)
55.26B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
405.42B
Total Debt/Equity (mrq)
0.24%
Levered Free Cash Flow (ttm)
14.08B